Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Entrada Therapeutics, Inc. (TRDA)
|
Add to portfolio |
|
|
|
| Price: |
$16.00
| | Metrics |
| OS: |
33.3
|
M
| |
-31
|
% ROE
|
| Market cap: |
$532
|
M
| |
-21
|
% ROIC
|
|
Net cash:
|
$377
|
M
| |
$11.32
|
per share
|
|
EV:
|
$156
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($71.3)
|
M
| |
|
|
|
EBIT
|
($73.6)
|
M
| |
|
|
| EPS |
($2.05)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 0.0 | 0.0 | 8.2 |
| Revenue growth | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 11.8 |
| Gross profit | 0.0 | 0.0 | 0.0 | -3.6 |
| Gross margin | | | | -43.9% |
| Research and development | 66.6 | 35.9 | 21.1 | |
| General and administrative | 30.6 | 15.2 | 5.6 | 3.6 |
| EBIT | -97.2 | -51.1 | -26.7 | -11.8 |
| EBIT margin | | | | -143.9% |
| Pre-tax income | -94.6 | -51.2 | -26.5 | -5.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -94.6 | -51.2 | -26.5 | -5.1 |
| Net margin | | | | -62.1% |
| |
| Diluted EPS | ($3.02) | ($8.16) | ($24.00) | ($5.47) |
| Shares outstanding (diluted) | 31.3 | 6.3 | 1.1 | 0.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|